VARICELLA-ZOSTER IMMUNE GLOBULIN (HUMAN) DIN 02231277
Status: Cancelled Post Market
Holder: MASSACHUSETTS PUBLIC HEALTH BIOLOGIC LABORATORIES
Molecule: VARICELLA ZOSTER IMMUNOGLOBULIN (HUMAN)
Health Canada record
| Active ingredient(s) | VARICELLA ZOSTER IMMUNOGLOBULIN (HUMAN) 100 UNIT |
|---|---|
| Dosage form | Liquid |
| Route | Intramuscular |
| Schedule | SCHEDULE D |
| Class | Human |
| ATC | J06BB03 VARICELLA/ZOSTER IMMUNOGLOBULIN |
| Original market date | 24-Jul-2000 |
| Current status date | 19-Jun-2007 |
| Source | Health Canada DPD |
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing VARICELLA ZOSTER IMMUNOGLOBULIN (HUMAN)
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02442183 | VARIZIG | KI BIOPHARMA LLC | Solution | VARICELLA ZOSTER IMMUNOGLOBULIN (HUMAN) 125 UNIT | Marketed |
| 00554286 | VARICELLA ZOSTER IMMUNE GLOBULIN INJ | MASSACHUSETTS PUBLIC HEALTH BIOLOGIC LABORATORIES | Liquid | VARICELLA ZOSTER IMMUNOGLOBULIN (HUMAN) 125 UNIT | Cancelled Post Market |
| 02243342 | VARIZIG | CANGENE CORPORATION A SUBSIDIARY OF EMERGENT BIOSOLUTIONS INC. | Kit | VARICELLA ZOSTER IMMUNOGLOBULIN (HUMAN) 125 UNIT | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 4111 | 1997-05-06 | New Drug Submission (NDS) |